CHINA BULLETIN: Manufacturing Contracts, Foreign Investment Plunges
In this week’s issue local governments line up for handouts, solar sector gets squeezed and Shein smiles on Britain’s Missguided fashion.
China’s mRNA pioneer Stemirna faces post-Covid reinvention test
The biopharma company that led the way in Chinese mRNA research is battling a wave of lawsuits and financial woes, including court limits on its founder’s spending Key Takeaways: Flush…
RELATED ARTICLES
-
Huawei rings up improbable comeback as revenue soars
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Shein loses its shine on bumpy path to London listing
- Huawei’s HarmonyOS NEXT faces major test with WeChat: Will it pass?
- Its shareholding reform rolled up, Honor is ready for IPO
- Apple’s AI gamble in China: Did it bet on the wrong horse?
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
